Neurocrine analysis sets 6-point EQ-VAS benchmark for meaningful health improvement in tardive dyskinesia
NBIX•Neurocrine Biosciences announced a 6-point EQ-VAS benchmark for clinically meaningful improvement in patient-reported overall health with Ingrezza for tardive dyskinesia. Findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, Oct. 26-29 in San Diego.
1. Health improvement benchmark
Neurocrine Biosciences announced an analysis establishing a 6-point EQ-VAS benchmark for clinically meaningful improvement in patient-reported overall health with Ingrezza for tardive dyskinesia. The benchmark supports previously reported KINECT-PRO findings showing meaningful improvements in overall health, daily functioning and involuntary movements. The findings will be presented at the Academy of Managed Care Pharmacy Nexus 2026 conference, Oct. 26-29 in San Diego.
